Cancer Institute– A national cancer institute
designated cancer center

Gary Dahl

Back to Profile

Publication Details

  • Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

    Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY, Raimondi SC, Onciu M, Jacobsen J, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D. J Clin Oncol. 2012; 30 (29): 3625-32

    In acute myeloid leukemia (AML), initial treatment response by morphologic analysis of bone marrow predicts long-term outcome. Response can now be assessed by minimal residual disease (MRD) monitoring with flow cytometry or polymerase chain reaction (PCR). We determined the relation among the results of these approaches and their prognostic value.

    PubMedID: 22965955

Stanford Medicine Resources:

Footer Links: